<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540692</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0419</org_study_id>
    <nct_id>NCT04540692</nct_id>
  </id_info>
  <brief_title>Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer</brief_title>
  <acronym>NEOSAMBA</acronym>
  <official_title>Phase III Randomized Clinical Trial Evaluating the Sequencing of Anthracyclines and Taxanes in Neoadjuvant Therapy for Locally Advanced HER2-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brazilian Breast Cancer Study Group (GBECAM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III randomized clinical trial evaluating the sequencing of anthracyclines and taxanes&#xD;
      in neoadjuvant therapy for locally advanced HER2-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicenter, phase III, open-label, randomized clinical trial, which will include 494&#xD;
      patients randomized to two neoadjuvant chemotherapy arms. The treatment protocol will be the&#xD;
      same in both groups, only the regimens sequences will be evaluated: starting with&#xD;
      anthracycline versus taxane, with or without carboplatin for patients with triple negative&#xD;
      subtype. The chemotherapy regimen will follow the institution's routine, which includes the&#xD;
      use of CA in the anthracyclical phase and, in the taxane phase, the use of docetaxel every 21&#xD;
      days or weekly paclitaxel. The rest of the treatment (surgery, radiotherapy, hormone therapy)&#xD;
      will not be part of the study and will be carried out according to institutional guidelines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">September 23, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive disease-free survival (IDFS)</measure>
    <time_frame>An average of 8 years</time_frame>
    <description>Defined as the time elapsed between the date of randomization and the date of invasive recurrence (excludes carcinoma in situ) or death, whichever comes first..</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">494</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Start with Cyclophosphamide + Doxorrubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the following treatment schedule: Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles, followed by docetaxel 75-100mg/m2 intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m2 for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Start with Docetaxel or Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the following treatment schedule: Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks, followed by Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days, for 3 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel or Paclitaxel</intervention_name>
    <description>Treatment will start with Docetaxel 75-100mg/m² intravenously every 21 days for 4 cycles or weekly paclitaxel 80mg/m² for 12 weeks</description>
    <arm_group_label>Start with Docetaxel or Paclitaxel</arm_group_label>
    <other_name>Taxotere or Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide + Doxorrubicin</intervention_name>
    <description>Treatment will start with Doxorubicin 60mg/m²; Cyclophosphamide 600mg/m² intravenously every 21 days for 3 cycles</description>
    <arm_group_label>Start with Cyclophosphamide + Doxorrubicin</arm_group_label>
    <other_name>Citoxan + Rubidox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female participants, with at least 18 years old on the day of signing the free and&#xD;
             informed consent;&#xD;
&#xD;
          -  Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative), according&#xD;
             to TNM 8th edition; Histologically confirmed diagnosis of invasive breast carcinoma&#xD;
             (with any histology), HER-2 negative;&#xD;
&#xD;
          -  The participant (or legally acceptable representative, if applicable) provides written&#xD;
             informed consent for the study;&#xD;
&#xD;
          -  The participant must agree to use a contraceptive as detailed in Appendix B of this&#xD;
             protocol during the treatment period and for at least 120 days after the last dose of&#xD;
             the study treatment;&#xD;
&#xD;
          -  Have a functional capacity according to the Eastern Cooperative Oncology Group (ECOG)&#xD;
             from 0 to 2. The evaluation of the ECOG must be carried out within 7 days before the&#xD;
             inclusion date.&#xD;
&#xD;
          -  Have adequate organic function. The samples must be collected within 60 days before&#xD;
             the start of the study treatment;&#xD;
&#xD;
          -  Have adequate cardiac function as assessed by echocardiogram or MUGA performed up to&#xD;
             60 days before the start of treatment under study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Individuals who do not meet the inclusion criteria above-mentioned.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Bines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional do Câncer - INCA - HCIII</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>José Bines, MD</last_name>
    <phone>+55 21 3207-3810</phone>
    <email>jose_bines@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gustavo Werutsky, MD</last_name>
    <phone>+55 51 3384-5334</phone>
    <email>gustavo.werutsky@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Pesquisa do Setor de Ginecologia e Mama do Hospital Araújo Jorge</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldo Queiroz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICTr</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Adriano Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Jardim Amália</name>
      <address>
        <city>Volta Redonda</city>
        <state>Rio De Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Lima</last_name>
    </contact>
    <investigator>
      <last_name>Heloísa Resende, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica da Liga Norte Riograndense Contra o Câncer</name>
      <address>
        <city>Natal</city>
        <state>Rio Grande Do Norte</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Emerenciano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Liedke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa em Oncologia PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisas Oncológicas - CEPON</name>
      <address>
        <city>Florianópolis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yeni Veronica Nerón, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Camila Alfano</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Zylberberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IBCC</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juliana Fenerich Mauri</last_name>
    </contact>
    <investigator>
      <last_name>Felipe Jose Silva Melo Cruz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

